Exelixis shares are scheduled to resume trading at 4:35 pm ET, with quotation set to resume at 4:30 pm ET, according to Nasdaq. The stock was halted, pending news, ahead of the company announcing that the phase 3 CONTACT-01 study evaluating cabozantinib in combination with atezolizumab did not meet its primary endpoint of overall survival at the final analysis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EXEL: